ACHP Behavioral Health Medical Directors
Use of NQF and NQMC Behavioral Health Measures: By Measure
Measure / PlansNQF 0576: Follow-Up After Hospitalization for Mental Illness / 11
NQF 0105: New Episode of Depression: (a) Optimal Practitioner Contacts for Medication Management, (b) Effective Acute Phase Treatment, (c) Effective Continuation Phase Treatment / 10
NQF 0004: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (a) Initiation, (b) Engagement / 9
NQF 0108: ADHD: Follow-Up Care for Children Prescribed Attention Deficit Hyperactivity Disorder (ADHD) Medication. a. Initiation Phase, b. Continuation and Maintenance (C&M) Phase / 8
NQF 1937: Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) / 8
NQF 0712: Depression Utilization of the PHQ-9 Tool / 5
NQMC 005108: The percentage of patients on the diabetes register and/or coronary heart disease CHD register for whom case finding for depression has been undertaken on one occasion during the previous 15 months using two standard screening questions. / 5
NQF 0008: Experience of Care and Health Outcomes (ECHO) Survey / 3
NQF 0027: Medical Assistance With Smoking and Tobacco Use Cessation / 3
NQF 0028: Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention / 3
NQF 0552: HBIPS-4: Patients discharged on multiple antipsychotic medications / 3
NQF 0557: HBIPS-6 Post Discharge continuing care plan created / 3
NQF 0418: Screening for clinical depression / 2
NQF 0552: HBIPS-4: Patients discharged on multiple antipsychotic medications / 2
NQF 0558: HBIPS-7 Post Discharge continuing care place transmitted to next level of care provider upon discharge / 2
NQF 0711: Depression Remission at Six Months / 2
NQF 1932: Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications / 2
NQF 1932: Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications / 2
NQF Candidate 1661—SUB-1: Alcohol Use Screening / 2
NQF Candidate 1663—SUB-2: Alcohol Use Brief Intervention Provided or Offered / 2
NQF Candidate 1664—SUB-3: Alcohol and Other Drug Use Disorder Treatment Provided or Offered at Discharge / 2
NQF Candidate 1665—SUB-4: Alcohol and Drug Use: Assessing status after discharge / 2
NQF 0003: Bipolar Disorder: Assessment for Diabetes / 1
NQF 0103: Major Depressive Disorder: Diagnostic Evaluation / 1
NQF 0104: Major Depressive Disorder: Suicide Risk Assessment / 1
NQF 0106: Diagnosis of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents / 1
NQF 0107: Management of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents / 1
NQF 0109: Bipolar Disorder and Major Depression: Assessment for Manic or hypomanic behaviors / 1
NQF 0110: Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use / 1
NQF 0111: Bipolar Disorder: Appraisal for risk of suicide / 1
NQF 0518: Depression Assessment Conducted / 1
NQF 0544: Use and Adherence to Antipsychotics among members with schizophrenia / 1
NQF 0560: HBIPS-5: Patients discharged on multiple antipsychotic medication with appropriate justification / 1
NQF 0640: HBIPS-2: Hours of physical restraint use / 1
NQF 0641: HBIPS-3: Hours of seclusion use / 1
NQF 0690: Percent of residents who have depressive symptoms (long stay) / 1
NQF 0710: Depression Remission at Twelve Months / 1
NQF 1385: Developmental screening using a parent completed screening tool (Parent report, Children 0-5) / 1
NQF 1399: Developmental Screening by 2 Years of Age: / 1
NQF 1448: Developmental Screening in the First Three Years of Life / 1
NQF 1515: Depression Screening by 18 years of age / 1
NQF 1515: Depression Screening by 18 years of age / 1
NQF 1879: Adherence to Antipsychotic Medications for Individuals with Schizophrenia / 1
NQF 1927: Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications / 1
NQF 1927: Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications / 1
NQMC 004208: Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current opioid addiction who were counseled regarding psychosocial AND pharmacologic treatment options for opioid addiction within the 12 month reporting period / 1
NQMC 004458: - Preventive care and screening: percentage of patients aged 18 years and older who were screened for unhealthy alcohol use at least once during the two-year measurement period using a systematic screening method AND who received brief counseling if identified as an unhealthy alcohol user / 1
No plans are tracking the following measures:
ACHP Behavioral Health Medical Directors
Use of NQF and NQMC Behavioral Health Measures: By Measure
- NQF 0112: Bipolar Disorder: Level-of-function evaluation
- NQF 0560: HBIPS-5 Patients discharged on multiple antipsychotic medication with appropriate justification
- NQF 0580: Bipolar antimanic agent
- NQF 0595: Lithium: Annual Lithium Test in ambulatory setting
- NQF 0596: Lithium: Annual Thyroid Test in ambulatory setting
- NQF 0609: Lithium: Annual Creatinine Test in ambulatory setting
- NQF 0690: Percent of residents who have depressive symptoms (long stay)
- NQF 0719: Children Who Receive Effective Care Coordination of Healthcare Services When Needed
- NQF 0722: Pediatric Symptom Checklist (PSC)
- NQF 0726: Inpatient Consumer Survey (ICS) consumer evaluation of inpatient behavioral healthcare services
- NQF 1364: Child and Adolescent Major Depressive Disorder: Diagnostic Evaluation
- NQF 1365: Child and Adolescent Major Depressive Disorder: Suicide Risk Assessment
- NQF 1394: Depression Screening by 13 years of age
- NQF 1406: Risky Behavior Assessment or Counseling by Age 13 years
- NQF 1507: Risky Behavior Assessment or Counseling by Age 18 years
- NQF 1933: Cardiovascular health monitoring for people with cardiovascular disease and schizophrenia
- NQF 1934: Diabetes monitoring for people with diabetes and schizophrenia